- Home
- ABLV vs NRXS Comparison
ABLV vs NRXS Comparison
Compare ABLV & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ABLV | NRXS |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | China | United States |
| Employees | 89 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 46.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ABLV | NRXS |
|---|---|---|
| Price | $0.69 | $6.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 5.2K | ★ 129.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,685,925.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $146.31 |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | ★ 9.18 |
| 52 Week Low | $0.59 | $1.33 |
| 52 Week High | $1.77 | $6.80 |
Technical Indicators
Market Signals| Indicator | ABLV | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 71.56 |
| Support Level | $0.60 | $2.32 |
| Resistance Level | $0.97 | N/A |
| Average True Range (ATR) | 0.03 | 0.49 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 24.24 | 74.96 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).